Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care.
about
Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam.Cost-minimization analysis of imipenem/cilastatin versus meropenem in moderate to severe infections at a tertiary care hospital in Saudi Arabia
P2860
Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Cost-utility analysis comparin ...... infections in intensive care.
@en
Cost-utility analysis comparin ...... infections in intensive care.
@nl
type
label
Cost-utility analysis comparin ...... infections in intensive care.
@en
Cost-utility analysis comparin ...... infections in intensive care.
@nl
prefLabel
Cost-utility analysis comparin ...... infections in intensive care.
@en
Cost-utility analysis comparin ...... infections in intensive care.
@nl
P2093
P1476
Cost-utility analysis comparin ...... infections in intensive care.
@en
P2093
Helen E Campbell
Jonathan M Plumb
Steven J Edwards
P2888
P356
10.1007/S10198-005-0333-Y
P577
2006-03-01T00:00:00Z